Literature DB >> 15804706

Anti-Ro/SSA and La/SSB antibodies.

F Franceschini1, I Cavazzana.   

Abstract

The Ro/La system is considered as an heterogeneous antigenic complex, constituted by three different proteins (52 kDa Ro, 60 kDa Ro and La) and four small RNAs particles. Anti-Ro/SSA are the most prevalent specificity among many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous LE (SCLE), neonatal lupus and primary biliary cirrhosis. In contrast, anti-La/SSB is more associated with Sjögren's syndrome (SS). The differences between 52 kDa, 60 kDa Ro and La could explain why different assays did not show equivalent performance in anti-Ro and anti-La autoantibodies detection. The RNA precipitation assay had the highest sensitivity and specificity, usually considered as the reference methods. CIE is considered the most reliable to detect anti-Ro/SSA antibodies in routine practice, performing better than immunoblotting (IB) and some ELISAs. It shows a high sensitivity (89%) and specificity (100%). ELISA is generally considered a safe, rapid, sensitive and specific tecnique. Therefore, its high sensitivity often corresponds to a very low clinical specificity and the assay can give false positive results. Therefore, it is very important to search anti-Ro and anti-La only in selected patients, using the assay with high specificity and good predictive value, in order to have clinically significant and true positive results.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804706     DOI: 10.1080/08916930400022954

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  57 in total

1.  Preclinical validation of salivary biomarkers for primary Sjögren's syndrome.

Authors:  Shen Hu; Kai Gao; Rodney Pollard; Martha Arellano-Garcia; Hui Zhou; Lei Zhang; David Elashoff; Cees G M Kallenberg; Arjan Vissink; David T Wong
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-08       Impact factor: 4.794

Review 2.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

3.  Sjögren's syndrome in patients with ankylosing spondylitis.

Authors:  Senol Kobak; Arzu Celebi Kobak; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2007-02       Impact factor: 2.980

4.  Spectrum of Neuro-Sjogren's syndrome in a tertiary care center in south India.

Authors:  Ravi Yadav; Pramod Krishnan; Girish Baburao Kulkarni; T C Yasha; M Veerendra Kumar; D Nagraja
Journal:  Ann Indian Acad Neurol       Date:  2011-04       Impact factor: 1.383

5.  Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays.

Authors:  Shen Hu; Arjan Vissink; Martha Arellano; Caroline Roozendaal; Hui Zhou; Cees G M Kallenberg; David T Wong
Journal:  Proteomics       Date:  2011-03-17       Impact factor: 3.984

Review 6.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

Review 7.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

8.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

9.  Psychiatric disorder as clinical presentation of primary Sjögren's syndrome: two case reports.

Authors:  Lorenzo Pelizza; Federica Bonacini; Alberto Ferrari
Journal:  Ann Gen Psychiatry       Date:  2010-04-01       Impact factor: 3.455

10.  Rapid serological detection of autoantibodies associated with Sjögren's syndrome.

Authors:  Peter D Burbelo; Kathryn H Ching; Alexandra T Issa; Caroline M Loftus; Yi Li; Minoru Satoh; Westley H Reeves; Michael J Iadarola
Journal:  J Transl Med       Date:  2009-09-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.